期刊文献+

冠心病合并血小板减少的分析与处理策略 被引量:2

Analysis and management of coronary heart disease complicated by thrombocytopenia
下载PDF
导出
摘要 目的总结冠心病患者合并血小板减少的因素及相应处理措施,为临床治疗提供参考。方法通过对文献及病例报道进行分析和总结。结果冠心病患者合并血小板减少主要分两种情况,一种为冠心病抗栓治疗引起的血小板减少,另一种为冠心病患者合并的其他系统疾病或同时应用的非抗栓药物引起的血小板减少。不同原因引起的血小板减少,相应的处理措施及对冠心病患者的预后影响不同。结论冠心病合并血小板减少直接影响冠心病的治疗策略,早期监测、识别血小板减少症,快速判断病因并采取适当措施可有效改善冠心病患者的预后。 Objective To summarize the factors and the corresponding treatments for patients with coronary heart disease(CHD)complicated by thrombocytopenia,and provide medical advises for clinical treatment.Methods Literatures and case reports were analyzed and summarized.Results Thrombocytopenia in patient with CHD could be mainly divided into two types,one group was induced by the antithrombotic therapies for CHD,and the other group was caused by some concurrent diseases or combined non-antithrombotic medications.There were different medical decisions and prognoses according to the causes in different groups.Conclusion The treatment strategies of CHD will be considered in the CHD patients with thrombocytopenia.Identifying thrombocytopenia by monitoring the platelet counts in early stage,finding out the causes quickly and providing proper treatments are the key for the prognosis of the patients.
作者 李星霞 霍炎 孙习鹏 陈燕 陆瑶华 郭澄 LI Xingxia;HUO Yan;SUN Xipeng;CHEN Yan;LU Yaohua;GUO Cheng(Department of Pharmacy,Shanghai Jiao Tong University Affiliated Sixth People's Hospital,Shanghai 200233,China)
出处 《药学实践杂志》 CAS 2020年第1期77-80,共4页 Journal of Pharmaceutical Practice
基金 上海交通大学医学院临床药学创新研究院青年项目(CXYJY2019QN003)
关键词 冠心病 急性冠脉综合征 血小板减少症 抗栓治疗 抗血小板治疗 抗凝治疗 coronary heart disease acute coronary syndrome thrombocytopenia antithrombotic therapy antiplatelet therapy anticoagulation treatment
  • 相关文献

参考文献2

二级参考文献19

  • 1O'Donnell J.Anticoagulants:therapeutics,risks,and toxicity-specialemphasis on heparin-induced thrombocytopenia ( HIT) [ J].JPharra Prac ,2012,25:22-29.
  • 2Warkentin TE.Think of HIT[ J].Hematology Am Soc Hematol EducProgram,2006:408-414.
  • 3Cuker A, Gimotty PA, Crowther MA, et al.Predictive value of the4Ts scoring system for heparin-induced thrombocytopenia: a system-atic review and meta-analysis [ J].Blood, 2012,120 ( 20): 4160-4167.
  • 4Jaax ME,Greinacher A.Management of heparin-induced Thrombo-cytopenia [J] .Expert Opin Pharmacother, 2012 ,13(7):987 -1006.
  • 5Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004,126(3 Suppl) :311S-337S.
  • 6Kelton JG, Hursting M J, Heddle N, et al. Predictors of clinical outcome in patients with heparin-induced thrombocytopenia treated with direct thrombin inhibition. Blood Coagul Fibrinolysis, 2008, 19:471-475.
  • 7Kejariwal D. Heparin-induced thrombocytopenia: a complication of thromboprophylaxis. J Bone Joint Surg Br, 2006,88:392-393.
  • 8Ahmed I, Majeed A, Powell R. Heparin induced thrombocytopenia: diagnosis and management update. Postgrad Med J, 2007,83:575-582.
  • 9Suvarna S, Espinasse B, Qi R, et al. Determinants of PF4/ heparin immunogenicity. Blood, 2007,110:4253-4260.
  • 10Warkentin TE, Sheppard JA, Sigouin CS, et al. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood ,2006,108:2937-2941.

共引文献49

同被引文献11

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部